Glucose-lowering drugs generally need to be metabolized by the liver and kidneys, and may have a certain effect on both the liver and kidneys. You can choose glucose-lowering drugs that have less effect on the liver and kidneys, including dipeptidyl peptidase IV inhibitors, sodium-glucose cotransporter protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and so on. 1. Dipeptidyl peptidase IV inhibitors: e.g., Riglitazone, studies have shown that Riglitazone does not increase the risk of the renal composite outcome (renal death, progression to end-stage renal disease, or sustained glomerular filtration rate decline ≥40%). 2. sodium-glucose cotransporter protein 2 inhibitors: e.g. dagliflozin, studies have shown cardiovascular and renal benefits of dagliflozin, a glucose-lowering drug that lowers blood glucose in the body by increasing urinary glucose. 3. glucagon-like peptide-1 receptor agonists: e.g. liraglutide, which studies have shown to reduce the renal composite endpoint (new onset of massive proteinuria, a 30% decrease in glomerular filtration rate, progression to end-stage renal disease, or death due to kidney disease) by 17%. It is important to seek medical attention if symptoms related to liver and kidney injury occur while on glucose-lowering medications to avoid delays.